STOCK TITAN

Leap Therapeutics to Present at Upcoming Virtual Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Leap Therapeutics, Inc. (Nasdaq:LPTX) announced that its CEO, Douglas E. Onsi, will present a corporate overview at two upcoming virtual investor conferences. The first is the Raymond James 42nd Annual Institutional Investors Conference on March 1, 2021 at 10 a.m. Eastern Time. The second is the H.C. Wainwright Global Life Sciences Conference from March 9-10, 2021, with a presentation available at 7:00 a.m. Eastern Time on March 9. Leap focuses on developing targeted and immuno-oncology therapeutics, with its leading candidate, DKN-01, in clinical trials for various cancers.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., Feb. 22, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the following virtual investor conferences:

Raymond James 42nd Annual Institutional Investors Conference
Date: Monday, March 1
Presentation Time: 10 a.m. Eastern Time

H.C. Wainwright Global Life Sciences Conference
Date: Tuesday, March 9Wednesday, March 10

The H.C. Wainwright presentation will be available on Tuesday, March 9, 2021 at 7:00 a.m. Eastern Time and may be accessed on the Investors page of the company's website at https://investors.leaptx.com/, and a live webcast of the Raymond James presentation can be accessed in the same section of the Company's website. A replay of the events will also be available for a limited time.

About Leap Therapeutics

Leap Therapeutics (Nasdaq:LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has entered into a strategic partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand. For more information about Leap Therapeutics, visit http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements include Leap's expectations with respect to the development and advancement of DKN-01, including the initiation, timing and design of future studies, enrollment in future studies, potential for the receipt of future option exercise, milestones or royalty payments from BeiGene, and other future expectations, plans and prospects. Although Leap believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from our expectations. Such risks and uncertainties include, but are not limited to: that the initiation, conduct, and completion of clinical trials, laboratory operations, manufacturing campaigns, and other studies may be delayed, adversely affected, or impacted by COVID-19 related issues; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates; the size and growth potential of the markets for our drug product candidates; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially will be included in Leap Therapeutics' periodic filings with the SEC, including Leap's Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as filed with the SEC on March 16, 2020 and as may be updated by Leap's Quarterly Reports on Form 10-Q and the other reports Leap files from time to time with the SEC. Any forward-looking statements contained in this release speak only as of its date. Leap undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

CONTACT:

Douglas E. Onsi
President & Chief Executive Officer
Leap Therapeutics, Inc.
617-714-0360
donsi@leaptx.com

Heather Savelle
Investor Relations
Argot Partners
212-600-1902
heather@argotpartners.com

Leap Therapeutics logo (PRNewsfoto/LEAP Therapeutics)

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/leap-therapeutics-to-present-at-upcoming-virtual-investor-conferences-301232010.html

SOURCE Leap Therapeutics, Inc.

FAQ

When will Leap Therapeutics present at the Raymond James conference?

Leap Therapeutics will present at the Raymond James 42nd Annual Institutional Investors Conference on March 1, 2021, at 10 a.m. Eastern Time.

What is the date for the H.C. Wainwright Global Life Sciences Conference presentation?

The H.C. Wainwright Global Life Sciences Conference is scheduled for March 9-10, 2021, with Leap's presentation available on March 9, 2021, at 7:00 a.m. Eastern Time.

What is DKN-01 and its significance for Leap Therapeutics?

DKN-01 is Leap Therapeutics' leading clinical candidate, a humanized monoclonal antibody targeting the Dickkopf-1 protein, currently in trials for various cancers.

Where can I access Leap Therapeutics' presentation?

The presentations will be accessible on the Investors page of Leap Therapeutics' website.

What does Leap Therapeutics focus on?

Leap Therapeutics focuses on developing targeted and immuno-oncology therapeutics to treat various types of cancer.

Leap Therapeutics, Inc.

NASDAQ:LPTX

LPTX Rankings

LPTX Latest News

LPTX Stock Data

114.03M
38.26M
17.31%
41.64%
1.89%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE